Extracting genetic alteration information for personalized cancer therapy from ClinicalTrials.gov

Jun Xu1, Hee-Jin Lee1, Jia Zeng2

  • 1School of Biomedical Informatics, University of Texas Health Science Center at Houston, Houston, TX, USA.

Abstract

Insights

This study created a knowledge base of cancer treatment trials by automatically extracting genetic alteration information, aiding personalized cancer therapy research and patient guidance.

Area of Science:

  • Oncology
  • Bioinformatics
  • Genomics

Background:

  • Personalized cancer therapy relies on understanding targeted genetic alterations.
  • ClinicalTrials.gov is a key resource for cancer treatment trials.

Purpose of the Study:

  • To develop a knowledge base of cancer treatment trials annotated with genetic alteration information.
  • To facilitate personalized cancer therapy by curating data from ClinicalTrials.gov.

Main Methods:

  • A semi-automatic framework combining text processing and manual review was developed.
  • Document classification identified cancer trials; information extraction pinpointed gene-alteration pairs.
  • The framework was applied to ClinicalTrials.gov data and validated.

Main Results:

  • A knowledge base of 2024 cancer trials with genetic alteration annotations was created.
  • Automated identification achieved 0.9944 precision; gene-alteration extraction yielded 0.8300 precision and 0.6803 recall.
  • Analysis showed increased targeted therapy use and frequent gene-alteration pairs.

Conclusions:

  • The curated knowledge base is a valuable resource for physicians and patients.
  • It supports the growing trend of targeted therapies in cancer treatment.
  • This resource aids in navigating personalized cancer treatment options.

Related Concept Videos

Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
6.3K
Cancer02:18

Cancer

Cancers arise due to mutations in genes involved in the regulation of cell division, which leads to unrestricted cell proliferation. Modern science and medicine have made great strides in the understanding and treatment of cancer, including eradicating cancer in some patients. However, there is still no cure for cancer. This is largely due to the fact that cancer is a large group of many diseases.
55.5K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

1.7K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.1K
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
66
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

1.5K